Rekah Pharmaceutical Industry Ltd.

TASE:REKA 주식 보고서

시가총액: ₪167.1m

Rekah Pharmaceutical Industry 과거 수익 실적

과거 기준 확인 3/6

Rekah Pharmaceutical Industry의 수입은 연평균 -39.3%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 수입이 연평균 9.9%의 비율로 증가했습니다. 매출은 연평균 10.1%의 비율로 증가해 왔습니다. Rekah Pharmaceutical Industry의 자기자본이익률은 4%이고 순이익률은 2.1%입니다.

주요 정보

-39.3%

수익 성장률

-40.1%

EPS 성장률

Pharmaceuticals 산업 성장35.1%
매출 성장률10.1%
자기자본 수익률4.0%
순이익2.1%
최근 수익 업데이트30 Jun 2024

최근 과거 실적 업데이트

Recent updates

Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Shares Climb 30% But Its Business Is Yet to Catch Up

Jul 11
Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Shares Climb 30% But Its Business Is Yet to Catch Up

Here's Why Rekah Pharmaceutical Industry (TLV:REKA) Has A Meaningful Debt Burden

Jul 05
Here's Why Rekah Pharmaceutical Industry (TLV:REKA) Has A Meaningful Debt Burden

Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year

Dec 14
Here's Why Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) CEO May Not Expect A Pay Rise This Year

Rekah Pharmaceutical Industry (TLV:REKA) Has A Somewhat Strained Balance Sheet

Sep 12
Rekah Pharmaceutical Industry (TLV:REKA) Has A Somewhat Strained Balance Sheet

Estimating The Fair Value Of Rekah Pharmaceutical Industry Ltd. (TLV:REKA)

Jul 19
Estimating The Fair Value Of Rekah Pharmaceutical Industry Ltd. (TLV:REKA)

Rekah Pharmaceutical Industry's (TLV:REKA) Problems Go Beyond Weak Profit

Apr 13
Rekah Pharmaceutical Industry's (TLV:REKA) Problems Go Beyond Weak Profit

We Think Rekah Pharmaceutical Industry (TLV:REKA) Is Taking Some Risk With Its Debt

May 12
We Think Rekah Pharmaceutical Industry (TLV:REKA) Is Taking Some Risk With Its Debt

Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Might Deserve Your Attention Today

Apr 09
Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Might Deserve Your Attention Today

Does Rekah Pharmaceutical Industry's (TLV:REKA) Share Price Gain of 50% Match Its Business Performance?

Mar 12
Does Rekah Pharmaceutical Industry's (TLV:REKA) Share Price Gain of 50% Match Its Business Performance?

Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Feb 19
Rekah Pharmaceutical Industry Ltd.'s (TLV:REKA) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Is Rekah Pharmaceutical Industry (TLV:REKA) Using Too Much Debt?

Jan 29
Is Rekah Pharmaceutical Industry (TLV:REKA) Using Too Much Debt?

Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Is An Interesting Stock

Jan 08
Here's Why I Think Rekah Pharmaceutical Industry (TLV:REKA) Is An Interesting Stock

How Is Rekah Pharmaceutical Industry's (TLV:REKA) CEO Paid Relative To Peers?

Dec 18
How Is Rekah Pharmaceutical Industry's (TLV:REKA) CEO Paid Relative To Peers?

Investors Who Bought Rekah Pharmaceutical Industry (TLV:REKA) Shares Five Years Ago Are Now Up 33%

Nov 30
Investors Who Bought Rekah Pharmaceutical Industry (TLV:REKA) Shares Five Years Ago Are Now Up 33%

수익 및 비용 분석

Rekah Pharmaceutical Industry 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

TASE:REKA 수익, 비용 및 수입 (ILS Millions )
날짜수익수익G+A 비용R&D 비용
30 Jun 243247744
31 Mar 24332-6754
31 Dec 23322-7714
30 Sep 23315-8684
30 Jun 23309-3644
31 Mar 23299-2613
31 Dec 22292-2603
30 Sep 222874603
30 Jun 222753563
31 Mar 222725533
31 Dec 212647502
30 Sep 212625472
30 Jun 212739462
31 Mar 2126310451
31 Dec 2026511462
30 Sep 202407472
30 Jun 202215471
31 Mar 202154471
31 Dec 191963462
30 Sep 192016462
30 Jun 191955452
31 Mar 191967463
31 Dec 181998453
30 Sep 182020493
30 Jun 18206-8513
31 Mar 18208-11522
31 Dec 17201-21512
30 Sep 17204-31543
30 Jun 17208-22563
31 Mar 17209-20562
31 Dec 16218-11582
30 Sep 161858461
30 Jun 161958501
31 Mar 162045551
31 Dec 152103581
30 Sep 15258-7753
30 Jun 15259-7772
31 Mar 15265-5762
31 Dec 14216-1601
30 Sep 142736780
30 Jun 142697770
31 Mar 142748800
31 Dec 132708800

양질의 수익: REKA 은 높은 수익을 보유하고 있습니다.

이익 마진 증가: REKA 는) 과거에 수익을 냈습니다.


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: REKA 지난 5년 동안 수익을 창출하여 매년 -39.3% 수익을 올렸습니다.

성장 가속화: REKA 지난해 흑자를 기록해 5년 평균과 비교하기 어려운 수익 성장률을 보이고 있습니다.

수익 대 산업: REKA 작년에 수익을 올렸기 때문에 지난 해 수익 성장을 Pharmaceuticals 업계( 6% )와 비교하기가 어렵습니다.


자기자본 수익률

높은 ROE: REKA 의 자본 수익률( 4% )은 낮음으로 간주됩니다.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기